<DOC>
	<DOCNO>NCT02164344</DOCNO>
	<brief_summary>Combined antiretroviral therapy ( cART ) -treated patient increased mortality morbidity compare age-matched seronegative individual . This increased mortality morbidity associate immune activation persists also patient cART even undetectable level HIV-RNA blood . Indeed , HIV-infected patient , irrespective cART treatment , show high level activate T cell , inflammatory monocyte proinflammatory cytokine seronegative individual . Several putative cause residual inflammation propose include ongoing HIV replication low level , presence coinfections cytomegalovirus , microbial translocation . None cause mutually exclusive understanding degree three cause residual inflammation cART-treated individual require novel therapeutic intervention aim alleviated putative cause . In longitudinal study aim : 1. reduce microbial translocation induce inflammation cART-treated individual supplementation cART probiotic . 2. investigate potential benefit 24 week probiotic supplementation immune function immune activation status Indeed , early stage HIV infection associate dysbiosis GI tract microbiome reducted level bifidobacteria lactobacillus specie increase level potentially pathogenic proteobacteria specie .</brief_summary>
	<brief_title>Effects Probiotics Microbial Translocation Immune Activation Markers HIV-positive Patients Combined Antiretroviral Therapy</brief_title>
	<detailed_description />
	<criteria>HIV positive patient HIV viral load &lt; 50 copies/ml antiretroviral therapy least 2 year intestinal disease opportunistic disease pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Gut</keyword>
	<keyword>probiotic</keyword>
	<keyword>immune activation</keyword>
</DOC>